natgillin/translations-raw huggingface dataset:
0.4 mg / kg body weight intravenously as a bolus dose followed by 0.15 mg / kg body weight / hour as a continuous intravenous infusion for 2 - 10 days or longer if clinically needed.
0,4 mg / kg telesne mase intravensko v obliki bolusa temu sledi 0,15 mg / kg telesne mase / uro v obliki neprekinjene intravenske infuzije, ki traja 2 – 10 dni, ali tudi dlje, če je to klinično potrebno.
0.4 mg as needed
0,4 mg po potrebi
0.4 mg single dose
0,4 mg
0.4 mg single dose
enkratni odmerek
0.4 mg single dose
enkratni odmerek 0,4 mg
0.4 ml (10000 IU/ml)
(10000 i.e./ml)
0.4 ml (20,000 IU/ml)
0,4 ml (20.000 i.e./ml)
0.4 ml (200 µg/ml)
0,4 ml (100 µg/ml)
0.4 ml (200 µg/ml)
0,4 ml (25 µg/ml)
0.4 mL if you have been prescribed 8 mg)
0,4 ml, če vam je bil predpisan odmerek 8 mg)
0.4 mL in a 1 mL graduated syringe for Somatropin Biopartners 2 mg
0,4 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 2 mg
0.4 ml solution for injection (25 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,4 ml raztopine za injiciranje (25 µg/ml darbepoetina alfa) v napolnjenem injekcijskem peresniku z injekcijsko brizgo iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.4 ml solution for injection (25 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,4 ml raztopine za injiciranje (25 µg/ml darbepoetina alfa) v napolnjeni injekcijski brizgi iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.4 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
0,4 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
0.4 ml.(10,000 IU/ml°)
0,4 ml (10.000 i.e./ml)
0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.
0,4 ml/10 kg telesne mase ) pred operacijo, npr. istočasno z indukcijo anestezije.
0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.
0,4 ml/10kg telesne mase) pred operacijo, na primer ob indukciji anestezije.
0.4 ml/10 kg body weight).
0,4 ml/10 kg telesne mase ).
0.4 ml/10 kg body weight).
0,4 ml/10 kg telesne mase).
0.4 ml/5 kg body weight) before surgery.
0,4 ml/5 kg telesne mase) pred operacijo.
0.4 mmol/l for sevelamer hydrochloride tablets).
1,7 ± 0,4 mmol/l za tablete sevelamerijevega klorida).
0.4 Units/kg insulin glulisine, respectively, and was 83.1±72.8 mg/kg and 112.3±70.8 mg/kg with 0.2 and 0.4 Units/kg insulin lispro respectively.
0,2 enot/kg insulina lispro je bila 83,1 ± 72,8 mg/kg, pri odmerku 0,4 enot/kg insulina lispro pa 112,3 ± 70,8 mg/kg.
0.4 Units/kg insulin glulisine, respectively, and was 83.1±72.8 mg/kg and 112.3±70.8 mg/kg with 0.2 and 0.4 Units/kg insulin lispro respectively.
0,2 enot/kg insulina lispro je bila 83,1 ±72,8 mg/kg, pri odmerku 0,4 enot/kg insulina lispro pa 112,3 ± 70,8 mg/kg.
0.4 Units/kg.
0,4 enot/kg sorazmerna z odmerkom.
0.4% of patients treated with alirocumab 300 mg every 4 weeks/150 mg every 2 weeks developed neutralizing antibodies (NAb) on at least one occasion with no loss of efficacy observed; no NAb were observed in patients treated with control.
Nevtralizirajoča protitelesa (NPt) so se ob vsaj eni priložnosti pojavila pri 0,4 % bolnikov, zdravljenih s 300 mg alirokumaba na 4 tedne/150 mg na 2 tedna, in to brez izgube učinkovitosti; pri kontrolnih bolnikih niso opažali NPt.
0.40 – 0.97 p=0.0380
0,40 – 0,97 p = 0,0380
0.40 – 0.97 p=0.0383
0,40 – 0,97
0.42 U/kg
0,42 i.e./kg
0.42, respectively; p=0.036).
0,42; p = 0,036).
0.44 mmol of sodium per vial.
0,44 mmol natrija na vialo.
0.45 mg/bazedoxifene 20 mg during months 10 to 12.
0,45 mg CE/20 mg bazedoksifena, med 10. in 12. mesecem zdravljenja.
0.45 micrograms once weekly
0,45 mikrogramov enkrat na teden.
0.45 ml twice daily
0.45 ml dvakrat na dan
0.47
2,6d
0.47
NR
0.47 – 0.80 p=0.0003
0,47 – 0,80
0.47AB[-0.58; -0.36]
7,9→7,4
0.480 mL (833 IU/mL)
0,270 ml (833 i.e./ml)
0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16
Incidenca primerov sepse s smrtnim izidom je bila povečana pri bolnikih s telmisartanom (0,33 %) v primerjavi z bolniki s placebom (0,16 %) [RR 2,07 (95 % interval zaupanja 1,14 – 3,76)].
0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
Pri bolnikih, ki so jemali telmisartan (0,33 %), se je v primerjavi s placebom (0,16 %) povečala pojavnost usodne sepse [RR 2,07 (95 odstotni interval zaupanja 1,14 do 3,76)].
0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
Pri bolnikih, ki so jemali telmisartan (0,33 %), se je v primerjavi s placebom (0,16 %) povečala pojavnost usodne sepse [RR 2,07 (95-odstotni interval zaupanja 1,14 do 3,76)].
0.49-0.93
p =
0.491 (0.290 to
0,491 (0,290-0,831)
0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01 - 1.27 MeV).
0,445 MeV in 0,492 MeV), delež, ki jo oddajajo v obliki žarkov gama, pa je 1,1 % (razpon energije 0,01 – 1,27 MeV).
0.5 for recovery of 2.0%).
0,5 fyrir aukningu upp á 2,0%).
0.5 for recovery of 2.0%).
0,5 za 2,0 % normalne aktivnosti).
0.5 g SACHET
0.5 g VREČICA
0.5 g tazobactam
0,5 g tazobaktama
0.5 g x 12 sachets
0,5 g x 12 vrečic
0.5 L/min/m2, the mean decrease in mean pulmonary arterial pressure was 8 mmHg, and the mean decrease in PVR was 389 dyn·sec·cm-5.
8 mm Hg in povprečno zmanjšanje PŽU 389 din·s·cm-5.
0.5 mg
0,5 mg in
0.5 mg (n=132)
0,5 mg (n=132)
0.5 mg + Laser n=118
ranibizumab 0,5 mg + laser n=118
0.5 mg + laser n=83
0,5 mg + laserja
0.5 mg and 1.0 mg
0,5 mg in
0.5 mg every 48 hours
0,5 mg vsakih 48 ur
0.5 mg every 5-7 days
0,5 mg vsakih 5-7 dni
0.5 mg every 72 hours
0,5 mg vsakih 72 ur
0.5 mg n=115
ranibizumab 0,5 mg n=115
0.5 mg single dose
0,5 mg enkratni odmerek
0.5 mg single dose
enkraten odmerek 0,5 mg
0.5 mg single dose
Posamezen odmerek 0,5 mg
0.5 mg tablets are white, 1 mg tablets are yellow and 2 mg tablets are peach-coloured.
0,5-mg tablete so bele, 1-mg tablete rumene, 2-mg tablete pa breskove barve.
0.5 mg twice daily
0,5 mg dvakrat na dan
0.5 mg/kg weekly
0,5 mg/kg/teden
0.5 mg/kg/week) should not be exceeded as there is limited experience with higher doses in this patient group.
0,5 mg/kg/teden) ni dovoljeno prekoračiti, saj je izkušenj z višjimi odmerki pri tej skupini bolnikov malo.
0.5 mg/ml dexmedetomidine hydrochloride
0,5 mg/ml deksmedetomidinijevega klorida
0.5 milligrams of palonosetron).
0,5 miligramom palonosetrona).
0.5 ml
Intramuskularna
0.5 mL
ubkutana
0.5 mL (0.5 mg/mL) 1 pre-filled syringe
0,5 ml (0,5 mg/ml) 1 napolnjena
0.5 ml (10 million IU/ml)
0,5 ml (10 milijonov i.e./ml)
0.5 ml (10 million IU/ml)
0,5 ml (10 milijonov i.e/ml)
0.5 ml (10,000 IU/ml)
0,5 ml (10.000 i.e./ml)
0.5 mL (100 IU/mL)
0,5 ml (100 i.e./ml)
0.5 ml (100 µg/ml)
0,5 ml (200 µg/ml)
0.5 ml (10000 IU/ml)
(10000 i.e./ml)
0.5 ml (12 m IU/ml)
0,5 ml (12 milijonov i.e./ml)
0.5 ml (12 million IU/ml)
0,5 ml (12 milijonov i.e./ml)
0.5 mL (150 IU/mL)
0,5 ml (150 i.e./ml)
0.5 ml (2,000 IU/ml)
0,5 ml (2.000 i.e./ml)
0.5 ml (20,000 IU/ml)
0,5 ml (20.000 i.e./ml)
0.5 mL (200 IU/mL)
0,5 ml (200 i.e./ml)
0.5 ml (24 million IU/ml)
0,5 ml (24 milijonov i.e./ml)
0.5 mL (300 IU/mL)
0,5 ml (300 i.e./ml)
0.5 ml (4,000 IU/ml)
0,5 ml (4.000 i.e./ml)
0.5 ml (40 µg/ml)
0,5 ml (200 µg/ml)
0.5 mL (400 IU/mL)
0,5 ml (400 i.e./ml)
0.5 ml (40000 IU/ml)
(10000 i.e./ml)
0.5 ml (40000 IU/ml)
(40000 i.e./ml)
0.5 ml (6 million IU/ml)
0,5 ml (6 milijonov
0.5 ml (6 million IU/ml)
0,5 ml (6 milijonov i.e./ml)
0.5 ml (6 million IU/ml)
milijonov i.e./ml)
0.5 ml (Fill 0.61 ml)
0,5 ml (polnitev 0,61 ml)
0.5 ml / kg bw
0,5 ml / kg tm
0.5 ml 10 pre-filled syringe (Luer Lock) + 10 needles
brizg (Luer Lock) + 10 igel
0.5 mL Booster Dose N=67
0,5 ml obnovitvenega odmerka
0.5 ml dose contains:
Odmerek (0,5 ml) vsebuje:
0.5 ml for the injections at day 7, 9, 11 of therapy, or
0,5 ml za injekcije na 7., 9. in 11. dan zdravljenja ali
0.5 ml N=628
0,5 ml n = 628
0.5 ml of solution (corresponding to 3 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in an flip-off seal (aluminium) with a bonnet (polypropylene). with 1 injection syringe, 1 injection needle and 1 cleansing swab.
0,5 ml raztopine (kar ustreza 3 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena), z 1 injekcijsko brizgo, 1 injekcijsko iglo in 1 čistilnim tamponom.
0.5 ml of solution (corresponding to 5 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene)
0,5 ml raztopine (kar ustreza 5 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena).
0.5 ml of solution for injection in 1.5 ml cartridge (type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a rubber inlay.
0,5 ml raztopine za injiciranje v 1,5 ml vložku (steklo tipa I) z batnim zamaškom (halobutilna guma) in aluminijasto zgibano zaporko z gumijasto notranjo prevleko.
0.5 ml of solution for injection in pre-filled syringe (siliconised Type I glass) with a plunger stopper and tip cap (butyl rubber laminated on the product facing side with fluororesin) with a needle.
0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi (silikonsko steklo tipa I) z zamaškom in in batom ter pokrovom na vrhu (iz butilirane gume, prevlečene z laminatom in fluorescinom na strani, ki je obrnjena proti zdravilu), injekcijska igla.
0.5 mL of solution in a pre-filled syringe (type I glass) with a plunger stopper (halobutyl rubber) and plunger (plastic), and with a needle for injection (stainless) – pack of 1.
0,5 ml raztopine v napolnjeni injekcijski brizgi (steklo tip I) z batnim zamaškom (halobutilna guma) in batom (plastičnim) ter injekcijsko iglo (nerjavečo) - pakiranje po 1.
0.5 ml of solvent in pre-filled syringe (glass) and plungers (plastic) for assembly with the pre-filled syringe.
0,5 ml vehikla v napolnjeni injekcijski brizgi (steklo) in bati (plastika) za sestavo z napolnjeno injekcijsko brizgo.
0.5 ml of suspension in a prefilled syringe (type I glass) with a plunger stopper (rubber butyl).
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (butilna guma).
0.5 ml of suspension in a vial (type I glass) for 1 dose with a stopper (rubber butyl) in the following pack sizes:
0,5 ml suspenzije v viali (steklo tipa I) za 1 odmerek z zamaškom (butilna guma) v naslednjih velikostih pakiranja:
0.5 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl) – pack size of 1.
0,5 ml suspenzije v viali (steklo tipa I) s potopnim zamaškom (butilna guma) – velikost pakiranja 1.
0.5 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl).
0,5 ml suspenzije v viali (steklo tipa I) z batnim zamaškom (butilna guma).
0.5 ml of suspension in a vial (type I glass) with a stopper (butyl).
0,5 ml suspenzije v viali (steklo tipa I) z zamaškom iz butilne gume.
0.5 ml of suspension in pre-filled syringe (type I glass) with a plunger stopper (rubber butyl) with or without separate needle in a pack size of 1, or without needles in a pack size of 10.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (butilna guma) s priloženo injekcijsko iglo ali brez v pakiranju po 1, ali brez priloženih injekcijskih igel v pakiranju po 10.
0.5 ml single dose in a pre-filled syringe + 1 needle.
0,5-mililitrski enkratni odmerek v napolnjeni injekcijski brizgi + 1 igla
0.5 ml single dose in a pre-filled syringe.
0,5-mililitrski enkratni odmerek v napolnjeni injekcijski brizgi
0.5 ml solution contains 250 micrograms of romiplostim (500 micrograms/ml).
0,5 ml raztopine 250 mikrogramov romiplostima (500 mikrogramov/ml).
0.5 ml solution for injection (40 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,5 ml raztopine za injiciranje (40 µg/ml darbepoetina alfa) v napolnjenem injekcijskem peresniku z injekcijsko brizgo iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.5 ml solution for injection (40 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,5 ml raztopine za injiciranje (40 µg/ml darbepoetina alfa) v napolnjeni injekcijski brizgi iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.5 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
0,5 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
0.5 mL solution in a pre-filled syringe (Type 1 glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex) in a pre-filled syringe.
0,5 ml raztopine v napolnjeni injekcijski brizgi (brizga iz stekla tipa 1) s pritrjeno iglo (iz nerjavečega jekla) in ščitnikom igle (iz gume, ki vsebuje lateks) v napolnjenem injekcijskem peresniku.
0.5 ml solution in a pre-filled syringe (type I glass) with a tip cap (bromobutyl rubber), a plunger stopper (teflonised chlorobutyl rubber) and an injection needle (stainless steel) or an injection needle (stainless steel) with a safety shield (safety needle) or an injection needle (stainless steel) with a safety device.
0,5 ml raztopine v napolnjeni injekcijski brizgi (steklo tipa I) z vrhnjo zaporko (iz bromobutilne gume), batnim zamaškom (iz teflonizirane kromobutilne gume) in injekcijsko iglo (iz nerjavnega jekla) ali injekcijsko iglo (iz nerjavnega jekla) z varnostnim pokrovčkom (z varnostno iglo) ali injekcijsko iglo (iz nerjavnega jekla) z varnostnim pripomočkom.
0.5 ml suspension for injection in pre-filled syringe (Type I glass) with a plunger rod (polypropylene), a plunger stopper (latex free grey butyl rubber) and a protective-tip cap (latex free grey butyl rubber) -
0,5 ml suspenzije za injiciranje v napolnjeni injekcijski brizgi (steklo tipa I) z ročajem bata (poliprolipen), zamašeni z batom (siva butilna guma brez lateksa) in zaščitnim pokrovčkom konice (siva butilna guma brez lateksa).
0.5 ml suspension in a pre-filled syringe (glass) with plunger stopper (siliconized FluroTec-laminated bromobutyl elastomer) and a tip cap (synthetic isoprene-bromobutyl blend) with two needles in pack size of 1 or 10.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo) z batom (s silikoniziranim FluoroTec-om obloženi bromobutilni elastomer) in pokrovčkom konice (sintetična izopren-brombutilna mešanica) ter z dvema iglama v pakiranjih po 1 ali 10.
0.5 ml suspension in a pre-filled syringe (type I glass) with a stopper (butyl rubber) with or without needles.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (iz stekla tipa I) z zamaškom (iz butilne gume), z iglami ali brez njih.
0.5 ml suspension in a vial (type I glass) with a stopper (butyl rubber).
0,5 ml suspenzije v viali (iz stekla tipa I) z zamaškom (iz butilne gume).
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), with 1 separate needle – pack size of 1 or 10.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (iz butila) in pokrovčkom (iz butila), z 1 ločeno iglo – velikost pakiranja 1 ali 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), with 2 separate needles – pack size of 1 or 10.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (iz butila) in pokrovčkom (iz butila), z 2 ločenima iglama – velikost pakiranja 1 ali 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), without needle – multipack of 5 packs of 10.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (iz butila) in pokrovčkom (iz butila), brez igle – skupno pakiranje 5 paketov po 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), without needle – pack size of 1 or 10.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (iz butila) in pokrovčkom (iz butila), brez igle – velikost pakiranja 1 ali 10.
0.5 ml suspension in pre-filled syringe (type I glass) with plunger stopper (halobutyl) and tip cap (halobutyl), without needle.
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (iz halobutila) in zaščiteni z zaporko (iz halobutila), brez igle.
0.5 ml twice daily
0.5 ml dvakrat na dan
0.5 ml) doses (21 days apart) of an AS03-containing vaccine containing HA from H1N1 manufactured using a different process there was an increase in injection site reactions and general symptoms after the second dose compared to the first dose.
0,5 ml) za odrasle (21 dni narazen) cepiva z AS03 z vsebnostjo HA iz H1N1v, pridobljenega z drugačnim postopkom, so po drugem odmerku v primerjavi s prvim odmerkom opazili več reakcij na mestu injiciranja in splošnih simptomov.
0.5 ml) doses or two half adult (i.e.
0,5 ml) ali dva polovična odmerka za odrasle (t.j.
0.5 ml) doses or two half adult (i.e.
0,5 ml) bodisi dva polovična odmerka za odrasle (tj.
0.5 ml) of Pandemrix were as follows:
0,5 ml) naslednji:
0.5 MU/kg/day (5 micrograms/kg/day) from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Dajati ga je treba od prvega dne po zaključeni kemoterapiji in dokler ne mine obdobje pričakovanega najmanjšega števila nevtrofilcev ter se njihovo število normalizira.
0.5 MU/kg/day (5 micrograms/kg/day) given daily from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Dajati ga je treba vsakodnevno od prvega dne po zaključeni kemoterapiji in dokler ne preide obdobje pričakovanega najmanjšega števila nevtrofilcev ter se njihovo število normalizira.
0.5 mU/L. In those patients with a normal TSH at baseline, elevation of TSH level above 0.5 mU/L was observed post baseline in 57% of lenvatinib-treated patients as compared with 14% of placebo-treated patients.
Pri bolnikih z normalnim TSH v izhodišču so ugotovili poizhodiščno zvišanje ravni TSH nad 0,5 me./l pri 57 % bolnikov, zdravljenih z lenvatinibom, v primerjavi s 14 % bolnikov, ki so prejemali placebo.
0.5 or 1 ml injection syringes (with scale intervals of 0.02 ml or smaller).
0,5 ali 1 ml injekcijske brizge (z merilno lestvico v razmikih po 0,02 ml ali manj).
0.5 ± 0.4
spreminjanje HAQ glede na
0.50 – 0.83 p=0.0007
0,50 – 0,83
0.51
DEFINE
0.51 (0.41, 0.62), p<0.0001
0,51 (0,41; 0,62), p < 0,0001
0.518 (p-value  0.0001)
0,518 (p-vrednost  0,0001)
0.54 (0.33, 0.89) p = 0.013**
0,54 (0,33; 0,.89) p = 0,013
0.54 ± 0.14 L/h/kg and 1.14 ± 0.31 L/h/kg.
0,54 ± 0,14 l/h/kg do 1,14 ± 0,31 l/h/kg.
0.56 – 0.93 p=0.0114
0,56 – 0,93 p = 0,0114
0.57 (0.45, 0.72) p<0.001
0,57 (0,45, 0,72) p < 0,001
0.57 – 0.95 p=0.020
0,57 – 0,95 p = 0,020
0.58
(95 % IZ)
0.58 (0.38, 0.87) (p=0.0084)
0,58 (0,38; 0,87) (p=0,0084)
0.58 days.
2,28 ± 0,58 dni.
0.58 x 109/L and absolute reticulocyte count was 24.3 x109/L. Eighty-six percent of patients were RBC transfusion dependent, and 91% were platelet transfusion dependent.
Šestinosemdeset odstotkov bolnikov je bilo odvisnih od transfuzij eritrocitov, 91 % pa jih je bilo odvisnih od transfuzij trombocitov.
0.5ml of water for injections with 3% (w/v) of mannitol
0,5 ml vode za injekcije s 3-odstotnim (m/v) manitolom
0.6 (10.1)†
bakterije v sputumu
0.6 kg for placebo was observed in the second phase (16 weeks) of the trial.
2,2 kg, v primerjavi z 0,6 kg pri bolnikih, ki so prejemali placebo.
0.6 mg liraglutide) and 16 units, respectively, and the dose was titrated twice weekly according to Table 2.
Odmerek so titrirali dvakrat na teden, kot je prikazano v preglednici 2.
0.6 ml (10000 IU/ml)
(10000 i.e./ml)
0.6 ml (16667 IU/ml)
0.6 ml (16667 i.e./ml)
0.6 ml (33333 IU/ml)
0.6 ml (33333 i.e./ml)
0.6 ml (50000 IU/ml)
0.6 ml (50000 i.e./ml)
0.6 mL in a 1 mL graduated syringe for Somatropin Biopartners 4 mg
0,6 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 4 mg
0.6 mL of solution (12 mg methylnaltrexone bromide)
0,6 ml raztopine (12 mg metilnaltreksonijevega bromida)
0.6 ml solution for injection (500 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,6 ml raztopine za injiciranje (500 µg/ml darbepoetina alfa) v napolnjenem injekcijskem peresniku z injekcijsko brizgo iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.6 ml solution for injection (500 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,6 ml raztopine za injiciranje (500 µg/ml darbepoetina alfa) v napolnjeni injekcijski brizgi iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.6 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
0,6 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
0.6 ml twice daily
0.6 ml dvakrat na dan
0.6 mmol (or 14 mg) sodium per vial.
0,6 mmol (ali 14 mg) natrija na vialo.
0.608
52.teden
0.61 (0.44, 0.85) (p=0.0038)
0,61 (0,44; 0,85) (p = 0,0038)
0.61 in males and females, respectively.
Srednje razmerje kri:plazma je pri moških 0,57, pri ženskah pa 0,61.
0.62
Negativno
0.63 U/kg
0,63 i.e./kg
0.63); p < 0.0001], and other types of bleeding (Table 6).
(95 % CI): 0,47 (0,34, 0,63); p < 0,0001] in drugih vrstah krvavitev (preglednica 6).
0.65 ml (200 µg/ml)
0,375 ml (40 µg/ml)
0.65 ml solution for injection (200 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
0,65 ml raztopine za injiciranje (200 µg/ml darbepoetina alfa) v napolnjenem injekcijskem peresniku z injekcijsko brizgo iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.65 ml solution for injection (200 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
0,65 ml raztopine za injiciranje (200 µg/ml darbepoetina alfa) v napolnjeni injekcijski brizgi iz stekla tipa 1 in nerjavečo jekleno iglo številka 27.
0.66
placebo
0.66 [0.54, 0.81] (p-value5 <0.0001)
0,66 [0,54, 0,81] (vrednost p5 < 0,0001)
0.660 (p-value = 0.00004)
0,660 (p-vrednost = 0,00004)
0.67 (0.41 – 1.10) p=0.1116
0,67 (0,41 – 1,10) p = 0,1116
0.67 (0.48–
o Pr 0.5
0.68 (0.59, 0.78) (p-value < 0.0001)
0,68 (0,59 ; 0,78) (p-vrednost < 0,0001)
0.68AC [0.53; 0.87]
0,22 (6,8 %)
0.695 (0.567, 0.852)
56,4 mesecev
0.7 mg/kg once daily
0,7 mg/kg enkrat na dan
0.7 mL in a 1 mL graduated syringe for Somatropin Biopartners 10 mg
0,7 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 10 mg
0.70
paritaprevir
0.70 (0.40, 1.23) (p=0.22)
0,70 (0,40; 1,23) (p=0,22)
0.70 (1 pipette)
0,70 (1 merilna kapalka)
0.70 (95% CI: 0.55, 0.90) (p-value = 0.0050e)
0,70 (0,55; 0,90) (p-vrednost = 0,0050e)
0.70 ml 2 pipettes Not applicable
EU/2/05/054/006
0.71
NR
0.71 (0.55, 0.92)
glatiramer
0.71 (0.68, 0.75)
Intrakranialne, n
0.71 points (SD: 2.14; 95% CI: –0.43–1.84)
0,71 točke (SD: 2,14, 95 %, CI: –0,43–1,84)
0.72 (0.60, 0.87) p=0.0008
0,72 (0,60; 0,87) p = 0,0008
0.72 ml (Fill: 0.88 ml)
0,72 ml (napolnjena: 0,88 ml)
0.73 (0.66-0.80)
pogostnost
0.734
Sekundarn i
0.74 [0.58, 0.94] (p-value5 = 0.0132)
0,74 [0,58, 0,94] (vrednost p5 = 0,0132)
0.74 L/h after a 1.5 mg/kg bw 6-hour intravenous infusion.
Povprečni očistek anti-Xa iz plazme po 6-urnem intravenskem infundiranju odmerka 1,5 mg/kg TM je 0,74 l/h.